Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Tonix Pharma ( (TNXP) ) just unveiled an update.
On June 11, 2025, Tonix Pharmaceuticals entered into a Sales Agreement with A.G.P./Alliance Global Partners to potentially sell up to $150 million in common stock, enhancing its financial flexibility. Additionally, Tonix signed a Purchase Agreement with Lincoln Park Capital Fund, allowing the sale of up to $75 million in newly issued shares, which could impact its market positioning by providing capital for general corporate purposes.
The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s score is primarily driven by positive corporate events and technical momentum. However, the lack of profitability and reliance on external funding weigh down the overall evaluation. The stock’s valuation reflects the typical risks and potential of biotech investments.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on developing and commercializing innovative therapies for central nervous system disorders and other unmet medical needs.
Average Trading Volume: 1,203,390
Technical Sentiment Signal: Sell
Current Market Cap: $276.4M
Learn more about TNXP stock on TipRanks’ Stock Analysis page.